KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EPS (Weighted Average and Diluted) (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $0.54 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 980.0% to $0.54 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.46, a 178.46% increase, with the full-year FY2025 number at $3.46, up 178.46% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.54 for Q4 2025 at Bristol Myers Squibb, down from $1.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.2 in Q1 2025 to a low of -$5.89 in Q1 2024.
  • A 5-year average of $0.45 and a median of $0.79 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 1275.0% in 2021, then tumbled 650.47% in 2024.
  • Bristol Myers Squibb's EPS (Weighted Average and Diluted) stood at $1.07 in 2021, then dropped by 11.21% to $0.95 in 2022, then fell by 8.42% to $0.87 in 2023, then crashed by 94.25% to $0.05 in 2024, then surged by 980.0% to $0.54 in 2025.
  • Per Business Quant, the three most recent readings for BMY's EPS (Weighted Average and Diluted) are $0.54 (Q4 2025), $1.08 (Q3 2025), and $0.64 (Q2 2025).